The effect of indacaterol on exercise tolelability

The effect of indacaterol on exercise tolelability - indacaterol and exercise tolelability

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009657

Enrollment

Registered

2013-01-04

Start date

2013-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive lung disease

Interventions

inhalation of indacaterol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) COPD is stable 2) be able to give written informed consent

Exclusion criteria

Exclusion criteria: 1) severe medical condition other than COPD. 2) arthral disease with pain which impairs walking. 3) a person who cannot uderstand the purpose and the method of this clinical study 4) a person who was assessed inappropriate for this clinical study

Design outcomes

Primary

Measure	Time frame
The improvement of endurance shattle walking test distance 30 days after the start of daily indacaterol.	—

Secondary

Measure	Time frame
1 The improvement of COPD assessment test score and dynamic hyperinflation 30 days after the start of daily indacaterol. 2. The improvement of FEV1 after indacaterol inhalation.	—

Countries

Japan

Contacts

Public ContactShinichiro Hayashi

Saga University Medical School Hospital Respirology

hayashs@cc.saga-u.ac.jp0952-34-2356

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026